1462876-11-4

1462876-11-4 structure

1462876-11-4 structure

Name: Clivatuzumab tetraxetan
Chemical Name: Clivatuzumab tetraxetan
CAS Number: 1462876-11-4
Molecular Formula:
Molecular Weight:
Catalog: Research Areas Cancer
Create Date: 2023-01-24 16:41:50
Modify Date: 2024-04-06 18:12:41
Clivatuzumab tetraxetan (IMMU107) is a humanized anti-MUC1 monoclonal antibody. Clivatuzumab tetraxetan shows anti-tumor activity. Clivatuzumab tetraxetan has the potential for the research of metastatic pancreatic cancer[1][2].

Name	Clivatuzumab tetraxetan

Description	Clivatuzumab tetraxetan (IMMU107) is a humanized anti-MUC1 monoclonal antibody. Clivatuzumab tetraxetan shows anti-tumor activity. Clivatuzumab tetraxetan has the potential for the research of metastatic pancreatic cancer[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vivo	Clivatuzumab tetraxetan (50, 100 µg; i.v.; once 以剂量依赖性方式减小肿瘤体积并增加小鼠的中位生存期[2]。 Animal Model: Nude mice (Capan-1 tumors)[2] Dosage: 50, 100 µg Administration: I.v.; once Result: Significantly decreased tumor volume in a dose-dependent manaer and increased the median survival to 13 weeks.
References	[1]. Shimizu M, et al. Thrombin-induced platelet aggregation -effect of dabigatran using automated platelet aggregometry. Platelets. 2020;31(3):360-364. [2]. Sharkey RM, et al. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol Cancer Ther. 2011 Jun;10(6):1072-81.

No Any Chemical & Physical Properties